Peak Bio (PKBO) and Its Rivals Head to Head Comparison

Earnings and Valuation

This table compares Peak Bio and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Peak Bio	$370,000.00	-$12.83 million	-0.14
Peak Bio Competitors	$551.75 million	-$35.20 million	3.30

Peak Bio’s competitors have higher revenue, but lower earnings than Peak Bio. Peak Bio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Peak Bio has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Peak Bio’s competitors have a beta of 1.09, suggesting that their average share price is 9% more volatile than the S&P 500.

Profitability

This table compares Peak Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	-172.56%
Peak Bio Competitors	-4,822.22%	-158.01%	-43.30%

Institutional & Insider Ownership

50.5% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 19.9% of Peak Bio shares are owned by company insiders. Comparatively, 15.9% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Peak Bio beats its competitors on 5 of the 9 factors compared.

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.